Ipsen (Euronext: IPN; ADR: IPSEY) today announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for Somatuline® Depot 120mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
In the European Union, Ipsen has submitted national marketing authorization variations for Somatuline® Autogel® 120mg injection to the drug regulatory authorities in 25 countries of the European Union.
Following EU and US submissions, Ipsen intends to implement worldwide submission roll-out.
Regulatory submission is supported by the results of the CLARINET® Phase III study, which demonstrated the antiproliferative effect of Somatuline® in the treatment of patients with GEP-NETs. The data from CLARINET® showed that investigational treatment with Somatuline® substantially prolonged time to disease progression or death versus placebo (hazard ratio 0.47, p=0.0002). Safety data generated from the CLARINET® study were consistent with the known safety profile of Somatuline®.
Marc de Garidel, Chairman and Chief Executive Officer of Ipsen stated: "There are significant unmet medical needs among GEP-NET patients and Ipsen is committed to help address them. The submission of supplemental marketing authorization applications in the US and variations in Europe for Somatuline® is evidence of our commitment to targeted oncology, and we are pleased to be able to submit them in our planned timeframe."
The data from CLARINET® is purely investigational, as Somatuline® is not authorized for the indication of antiproliferative treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in any market. In many countries where it is marketed as Somatuline® Autogel®, Somatuline® is approved for treatment of acromegaly and for the symptoms associated with neuroendocrine tumors, which can include the treatment of GEP-NET patients experiencing symptoms from carcinoid syndrome, and Somatuline® is approved in many countries for the treatment of acromegaly. Somatuline® Depot is approved in the US for the treatment of acromegaly but not for the treatment of GEP-NETs or the symptoms thereof.